MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. “We have continued to execute well across our business, including the achievement of... Read More

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase... Read More

MELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its first quarter 2025 financial results after market close on Wednesday, May 14, 2025. Following the announcement, BioRestorative management will... Read More

MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Vice President of Research and Development, Francisco Silva, will present an update on its ongoing Phase 2 clinical trial of BRTX-100 in chronic lumbar... Read More

MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern... Read More

MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: B R TX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body... Read More

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the year ended December 31, 2024 and provided an update on its business. “2024 was a transformative year for BioRestorative, highlighted by significantly improved... Read More

MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its 2024 financial results after market close on Thursday, March 27, 2025. Following the announcement, BioRestorative management will host a... Read More

BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting IND clearance expands Company’s advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain Company to host webcasted conference call today at 10:30am EST MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX”... Read More

MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The Company will now host the call at 10:30am EST on... Read More

MELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that it expects to provide a positive clinical pipeline update before market open on Thursday, February 27, 2025. “We very much look forward to updating investors... Read More

Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date May also lead to Priority Review and Accelerated Biologics License Application (“BLA”) Approval for BRTX-100 MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) ,... Read More

New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health” presentation Among other positive preliminary data analyses, comparison of MRI images to baseline potentially demonstrate disc microenvironment remodeling MELVILLE, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX... Read More

Covers cGMP manufacturing processes Expected to provide protection until April 29, 2040 MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the European Patent Office has issued a Notice of Allowance for a new... Read More

Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints Patient reported efficacy outcomes show a material decrease in pain and increase in function If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points The blinded preliminary BRTX-100 data to be described in a podium presentation this morning at the ORS PSRS 7th... Read More

MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended September 30, 2024 and provided an update on its business. “We have continued to execute well across all areas of our business and are... Read More

New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 Data will be on a significantly higher number of study subjects over a longer period of time than has been presented previously Company will also release its third quarter 2024 financial results and provide a business update on November 12, 2024 Webcasted conference... Read More

Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license... Read More

Further expands already formidable intellectual property estate the Company has been building for its novel ThermoStem ® technology platform MELVILLE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that the Israel... Read More

MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, announces the following investor events in October: UBS Virtual Organ Restoration and Cell Therapy Day: Lance Alstodt, BioRestorative’s Chief Executive Officer, will participate in a fireside chat... Read More

MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City. The event will consist... Read More

MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Scientist and Vice President of Research and Development, Francisco Silva, will present at the 21 st Annual International Federation for Adipose... Read More

MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter June 30, 2024 and provided an update on its business. “We have had an exciting and productive first half of 2004 and are energized by the many... Read More

MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024. Following the announcement, BioRestorative management will host a conference call to review... Read More

New journal section will focus on emerging and translation work in the field of regenerative medicine MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has... Read More

Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform Expanding intellectual property estate expected to help drive ThermoStem ® licensing opportunities Substantive discussions continue with commercial stage regenerative medicine company with regard to a license of ThermoStem ® IP MELVILLE, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or... Read More

Significant YoY improvement in operating performance Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has... Read More

Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders ThermoStem ® is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets Potential license partner is a leading commercial stage regenerative medicine company MELVILLE, N.Y., June 13, 2024... Read More

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings... Read More

MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, due to the Company's failure to timely file its... Read More

MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032 , growing at a CAGR of 13.34% between 2024 and 2032. Medical aesthetics, a subsection of the global aesthetics market, was estimated to be worth $15.4 billion in 2023 and is expected to... Read More

MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today provided an update on its business. “We have successfully executed against key strategic priorities since the start of the year,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “The most important of... Read More

New therapeutic candidate developed using Company’s patented ThermoStem ® platform Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss DMF submission and commencement of first-in-human studies targeted for before the end of 2024 Expanding the use of ThermoStem ® may open the door to big pharma partnership opportunities MELVILLE, N.Y., May 08, 2024... Read More

Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024... Read More

Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform Exclusive, five (5)-year agreement includes BioRestorative supplying its initial commercial product to Cartessa Financial impact from commercial partnership expected to provide flexibility for BioRestorative to become significantly less dependent on the capital markets for future... Read More

Amendment replaces saline injections with sham injections in the control group MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2... Read More

Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity Patient enrollment expected to be completed in 2024 MELVILLE, N.Y., April 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient... Read More

Company is not offering shares pursuant to the registration statement MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The registration statement... Read More

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023. The annual report can be accessed on the SEC's website at www.sec.gov ,... Read More

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California BioRestorative’s Chief Executive Officer, Lance Alstodt, is scheduled... Read More

MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $2.33 per... Read More

Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial Company to host webcasted conference call today at 8:30am EST MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented... Read More

Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST MELVILLE, N.Y., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that... Read More

Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., Dec. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and... Read More

MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference. Company BioRestorative Therapies, Inc. Presenter Lance Alstodt, Chief Executive Officer Date & Time... Read More

BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement Agreement Represents Initial Venture into the $62.8 Billion Global Aesthetics Market Initial Order of 5,000 Vials of Product Represents Controlled Launch and Will Have Positive Financial Impact MELVILLE, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.... Read More

Site activation allows for patients in the State of New York to participate in the BRTX-100 tria 15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New... Read More

MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point. BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") recently held a virtual panel about their stem cell-based therapies and... Read More

MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank. The license enables BioRestorative to process mesenchymal stem cells obtained from autologous donors. BioRestorative is now the... Read More

MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Company’s common stock at an offering price of $3.03 per share in a... Read More

MELVILLE, NY / ACCESSWIRE / July 7, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100. The independent review body Data Safety Monitoring Board (DSMB) which is overseeing dose and safety related issues during the course of the trial approved the trial's continuation with no changes to the current... Read More

No D ose L imiting T oxicity (DLT) w as O bserved in the P atients in the S afety R un- I n S egment of S tudy DSMB R ecommendation A llows f or O pen E nrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the independent Data Safety Monitoring... Read More

MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22 nd at 9:00 A.M.... Read More

Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100 MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the final subject in its BRTX-100 Phase 2 clinical trial safety... Read More

MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York. Senior management will also be available for one-on-one investor meetings... Read More

License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100 MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has received a license from the New York State Department of Health to... Read More

Upon issuance , patent will be the fourth Japanese patent to issue for the ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark... Read More

MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to address several medical conditions , including metabolic disorders such as Obesity, Type 2 Diabetes,... Read More

New York State’s largest health care provider will participate in BRTX’s clinical trial Expansive universe of patients and clinical sites from which to recruit high quality subjects Leverage Northwell’s “Center for Regenerative Orthopedic Medicine” Potential future collaborations to be explored in connection with basic science research MELVILLE, N.Y., May 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.... Read More

MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference taking place May 10 th to 11 th at the Plaza Hotel in New York City. The Inaugural EF Hutton Global Conference is a two-day,... Read More

Clinical data from safety run-in scheduled to be released in second half of 2023 MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting... Read More

Bruder Consulting & Venture Group engaged to expand BRTX-100 c linical indication p ipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has entered into an agreement with the Bruder Consulting & Venture Group (“BCVG”), a full service... Read More

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or body fat. A metabolic disorder can occur when the body's chemical reactions become abnormal. This results in metabolic syndrome, where there is an excess or scarcity of health-preserving essential substances. Metabolic syndrome... Read More

Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35 th Annual Conference being held from March 12 – 14 at The Ritz Carlton, Laguna Niguel in Dana Point, California. Lance Alstodt, President and CEO... Read More

Notice of allowance will be the third US patent to issue from this ThermoStem ® family targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office... Read More

Patent provides protection in key international markets for BioRestorative ’ s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes MELVILLE, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has... Read More

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. The company is engaged in developing therapeutic products using cell and tissue protocols, primarily with adult stem cells, for large multi-billion dollar markets that are underserved and affect millions of Americans, like chronic lower back pain and metabolic disorders. BioRestorative currently has two... Read More

Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company” ) (NASDAQ : BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for... Read More